The evolution of three decades of antiretroviral therapy: challenges, triumphs and the promise of the future.

Tseng A, Seet J, Phillips EJ
Br J Clin Pharmacol. 2015 79 (2): 182-94

PMID: 24730660 · PMCID: PMC4309625 · DOI:10.1111/bcp.12403

The evolution of human immunodeficiency virus (HIV) treatment has improved our understanding and management of complex pharmacological issues that have driven improved outcomes and quality of life of the HIV-infected patient. These issues include adherence, long- and short-term toxicities, pharmacoenhancement, pharmacogenomics, therapeutic drug monitoring, differential penetration of drugs into sanctuary sites, such as the central nervous system, genital tract and small bowel, and drug-drug and drug-food interactions related to cytochrome P450 drug-metabolizing enzymes, uridine diphosphate glucuronyltransferases and drug transporters, to name a few. There is future promise, as an increased understanding of the immunopathogenesis of HIV and global public health initiatives are driving novel treatment approaches with goals to prevent, control and, ultimately, eradicate HIV.

© 2014 The British Pharmacological Society.

MeSH Terms (10)

Anti-HIV Agents Drug Interactions Drug Monitoring Food-Drug Interactions Global Health HIV Infections Humans Patient Compliance Pharmacogenetics Quality of Life

Connections (1)

This publication is referenced by other Labnodes entities: